GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹5,967 Cr | ₹5,819 Cr | ₹4,546 Cr | ₹4,689 Cr | ₹4,201 Cr |
What is the latest Total Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹5,967 Cr |
| Mar2024 | ₹5,819 Cr |
| Mar2023 | ₹4,546 Cr |
| Mar2022 | ₹4,689 Cr |
| Mar2021 | ₹4,201 Cr |
How is Total Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,967 Cr | 2.55 | |
| Mar2024 | ₹5,819 Cr | 27.99 | |
| Mar2023 | ₹4,546 Cr | -3.05 | |
| Mar2022 | ₹4,689 Cr | 11.63 | |
| Mar2021 | ₹4,201 Cr | - | |
Compare Total Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹60,028.2 Cr | 3.2% | 4.6% | 50.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹428,185.0 Cr | 3% | 9.5% | 3.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,766.0 Cr | 1.7% | 3.1% | 5.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹148,923.0 Cr | 4.7% | 11.7% | 41.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹110,081.0 Cr | 2.1% | 6.7% | 11.6% | Stock Analytics | |
| CIPLA | ₹109,680.0 Cr | 1.3% | 1.3% | -9.4% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 3.2% |
4.6% |
50.6% |
| SENSEX | -0.3% |
-0.1% |
8.3% |
You may also like the below Video Courses